Sacyl Pharmaceuticals, Inc.

Sacyl Pharmaceuticals develops first-in-class systemic, non-hormonal, on-demand contraceptives for men and women by targeting soluble adenylyl cyclase. Their lead programs are in preclinical development with support from the Male Contraceptive Initiative and aim to provide fast acting, reversible male contraception. The company has received multiple grants to advance their sAC inhibitor compounds toward clinical trials[1][5][6][7].

Early results show promising pharmacological profiles of second-generation sAC inhibitors with slow dissociation rates[1].

The approach offers a temporary contraceptive effect by inhibiting sperm motility and fertilization capacity shortly after administration[6].